BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 34199060)

  • 1. Molecular Characteristics of RAGE and Advances in Small-Molecule Inhibitors.
    Kim HJ; Jeong MS; Jang SB
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34199060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting RAGE Signaling in Inflammatory Disease.
    Hudson BI; Lippman ME
    Annu Rev Med; 2018 Jan; 69():349-364. PubMed ID: 29106804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RAGE and its ligands: from pathogenesis to therapeutics.
    Jangde N; Ray R; Rai V
    Crit Rev Biochem Mol Biol; 2020 Dec; 55(6):555-575. PubMed ID: 32933340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective.
    Bongarzone S; Savickas V; Luzi F; Gee AD
    J Med Chem; 2017 Sep; 60(17):7213-7232. PubMed ID: 28482155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic potential of targeting the receptor for advanced glycation end products (RAGE) by small molecule inhibitors.
    Singh H; Agrawal DK
    Drug Dev Res; 2022 Sep; 83(6):1257-1269. PubMed ID: 35781678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The receptor for advanced glycation end-products (RAGE) is an important pattern recognition receptor (PRR) for inflammaging.
    Teissier T; Boulanger É
    Biogerontology; 2019 Jun; 20(3):279-301. PubMed ID: 30968282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycation reaction and the role of the receptor for advanced glycation end-products in immunity and social behavior.
    Leerach N; Harashima A; Munesue S; Kimura K; Oshima Y; Goto H; Yamamoto H; Higashida H; Yamamoto Y
    Glycoconj J; 2021 Jun; 38(3):303-310. PubMed ID: 33108607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of RAGE Axis Signaling: A Pharmacological Challenge.
    Rojas A; Morales M; Gonzalez I; Araya P
    Curr Drug Targets; 2019; 20(3):340-346. PubMed ID: 30124149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ousting RAGE in melanoma: A viable therapeutic target?
    Syed DN; Aljohani A; Waseem D; Mukhtar H
    Semin Cancer Biol; 2018 Apr; 49():20-28. PubMed ID: 29079306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RAGE: a multi-ligand receptor unveiling novel insights in health and disease.
    Alexiou P; Chatzopoulou M; Pegklidou K; Demopoulos VJ
    Curr Med Chem; 2010; 17(21):2232-52. PubMed ID: 20459381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Receptor for Advanced Glycation End Products (RAGE): A Pivotal Hub in Immune Diseases.
    Yue Q; Song Y; Liu Z; Zhang L; Yang L; Li J
    Molecules; 2022 Aug; 27(15):. PubMed ID: 35956875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response.
    Yan SF; Ramasamy R; Schmidt AM
    J Mol Med (Berl); 2009 Mar; 87(3):235-47. PubMed ID: 19189073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A fragment-based approach to discovery of Receptor for Advanced Glycation End products inhibitors.
    Kozlyuk N; Gilston BA; Salay LE; Gogliotti RD; Christov PP; Kim K; Ovee M; Waterson AG; Chazin WJ
    Proteins; 2021 Nov; 89(11):1399-1412. PubMed ID: 34156100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RAGE in the pathophysiology of skeletal muscle.
    Riuzzi F; Sorci G; Sagheddu R; Chiappalupi S; Salvadori L; Donato R
    J Cachexia Sarcopenia Muscle; 2018 Dec; 9(7):1213-1234. PubMed ID: 30334619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Trp triad within the V-domain of the receptor for advanced glycation end products modulates folding, stability and ligand binding.
    Indurthi VSK; Jensen JL; Leclerc E; Sinha S; Colbert CL; Vetter SW
    Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31912881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receptor for Advanced Glycation End Products (RAGE) in Type 1 Diabetes Pathogenesis.
    Leung SS; Forbes JM; Borg DJ
    Curr Diab Rep; 2016 Oct; 16(10):100. PubMed ID: 27612847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The biology of the receptor for advanced glycation end products and its ligands.
    Schmidt AM; Yan SD; Yan SF; Stern DM
    Biochim Biophys Acta; 2000 Dec; 1498(2-3):99-111. PubMed ID: 11108954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes.
    Stern DM; Yan SD; Yan SF; Schmidt AM
    Ageing Res Rev; 2002 Feb; 1(1):1-15. PubMed ID: 12039445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural basis for pattern recognition by the receptor for advanced glycation end products (RAGE).
    Xie J; Reverdatto S; Frolov A; Hoffmann R; Burz DS; Shekhtman A
    J Biol Chem; 2008 Oct; 283(40):27255-69. PubMed ID: 18667420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RAGE Signaling in Melanoma Tumors.
    Olaoba OT; Kadasah S; Vetter SW; Leclerc E
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33256110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.